In this issue:
CA-125 is not a reliable surrogate for progression during PARP inhibition
Oophorectomy reduces mortality risk in women with BRCA1/2 mutations
Asian age-specific ovarian cancer risks associated with BRCA1/2 variants
No benefit to addition of durvalumab to tremelimumab in platinum-resistant disease
Dual immunotherapy plus chemotherapy promising for platinum-resistant disease
OCTOVA: is olaparib + cediranib an option for platinum-resistant ovarian cancer?
Long-term update from the normal risk ovarian screening study
SeqOne HRD assay validated
Could increasing the scope of omentectomy improve outcomes?
Low-dose aspirin may lower risk of ovarian cancer in some women
Please login below to download this issue (PDF)